NCT06565546

CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia Repairs

Feasibility and Efficacy of CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia Repairs: A Pilot Pragmatic Trial

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: University of Florida · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Pilot pragmatic trial using an implementation science approach to determine the feasibility of a CYP2D6-guided opioid prescribing for patients undergoing elective VHRs compared to usual care. Assess the efficacy (PROMIS Pain Intensity and Hernia-Related QOL) of a CYP2D6-guided opioid prescribing approach for patients undergoing elective VHRs.

Conditions

• Ventral Hernia

Interventions

Type	Name	Description
OTHER	Opioid pain medication prescribed based on CYP2D6 genotype testing PLUS Acetaminophen and Gabapentin	CYP2D6 genotype testing for assessment of medication metabolism to guide prescription of postoperative pain medication
OTHER	Acetaminophen and Gabapentin: standard postoperative pain medications	Participants will receive standard postoperative pain medications

Timeline

• Start date: 2025-01-29
• Primary completion: 2026-06-01
• Completion: 2026-07-01
• First posted: 2024-08-22
• Last updated: 2026-01-08

Locations

1 site across 1 country: United States